Metagenomi Therapeutics, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-59.3% -$6M
$4M
R&D↓-7.2% -$2M
$22M
D&A↓-11.0% -$161K
$1M
Operating Income↓-2.0% -$456K
$-23M
EBITDA↓-11.0% -$161K
$1M
Interest Income↓-41.1% -$1M
$2M
Other Income/Expense↑+99.9% +$2M
$-2K
Pretax Income↑+1.2% +$252K
$-21M
Tax Provision
$34K
Net Income↓-8.6% -$2M
$-20M
Operating Margin↓-69.4pts
-263.8%
Net Margin↓-72.5pts
-235.5%
Effective Tax Rate↓-9.0pts
1.1%
ETR (Continuing Operations)↓-6.5pts
0.1%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↑+0.4pts
0.4%
Operating Lease Cost↑+14.0% +$170K
$1M
Revenue YoY Variation↓-36.9pts
-59.3%
Income YoY Variation↓-2.1pts
-2.0%
Revenue QoQ Variation↓-38.3pts
-54.8%
Income QoQ Variation↑+23.9pts
-8.8%